It is reported that K‐RAS or N‐RAS mutations account for 59% of pancreatic cancer, 39% of CRC, 30% of cancer of biliary tract, 17% of non‐small‐cell lung cancer (NSCLC), 15% of ovarian cancer, 15% of endometrium cancer, and 23% of blood cancer (Sanger Institute Cosmic Database) (Fernández‐Medarde and Santos, 2011; Forbes et al., 2011; Prior et al., 2012). The gene discussed is NRAS; the disease is colorectal carcinoma.